1Biochemistry Department, School of Biomedical Sciences, University of Otago, P.O. Box 56, 710 Cumberland Street, Dunedin 9054, New Zealand.
2Institute of Bioinformatics, University of Georgia, Athens, GA 30602, USA.
3Structural Genomics Consortium, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
4Division of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
5Department of Biochemistry & Molecular Biology, University of Georgia, Athens, GA 30602, USA.
3Structural Genomics Consortium, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
4Division of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
By Sam A. Jamieson, Zheng Ruan, Abigail E. Burgess, Jack R. Curry, Hamish D. McMillan, Jodi L. Brewster, Anita K. Dunbier, Alison D. Axtman, Natarajan Kannan, Peter D. Mace
Science Signaling
Allosteric regulation of the pseudokinase TRIB1 reveals the therapeutic potential of kinase inhibitors.
By Sam A. Jamieson, Zheng Ruan, Abigail E. Burgess, Jack R. Curry, Hamish D. McMillan, Jodi L. Brewster, Anita K. Dunbier, Alison D. Axtman, Natarajan Kannan, Peter D. Mace
Science Signaling
Allosteric regulation of the pseudokinase TRIB1 reveals the therapeutic potential of kinase inhibitors.